Response in peak IC | Treatment versus comparator, OR (95% CI) | |||||
---|---|---|---|---|---|---|
GFF MDI 18/9.6 μg n = 102 | Placebo MDI n = 99 | TIO SMI 5 μg n = 68 | GFF MDI vs placebo MDI | GFF MDI vs TIO SMI | TIO SMI vs placebo MDI | |
Patients achieving a response (evening), % | ||||||
> 10% | 83.5 | 31.5 | 71.1 | 11.00 (4.12–29.43) | 2.05 (0.83–5.10) | 5.36 (2.13–13.49) |
> 15% | 72.1 | 19.0 | 47.0 | 10.98 (4.34–27.79) | 2.91 (1.27–6.68) | 3.77 (1.58–8.98) |
> 20% | 54.8 | 15.3 | 31.4 | 6.70 (2.98–15.08) | 2.65 (1.27–5.51) | 2.53 (1.12–5.74) |
> 200 mL | 83.1 | 27.8 | 61.3 | 12.78 (4.70–34.79) | 3.12 (1.25–7.79) | 4.10 (1.68–9.99) |
> 300 mL | 66.3 | 20.0 | 43.4 | 7.84 (3.47–17.74) | 2.56 (1.22–5.37) | 3.06 (1.38–6.79) |
> 400 mL | 46.5 | 10.3 | 20.9 | 7.58 (3.09–18.63) | 3.29 (1.42–7.61) | 2.31 (0.89–5.96) |
Patients achieving a response (morning), % | ||||||
> 10% | 92.1 | 47.2 | 75.2 | 12.94 (4.57–36.68) | 3.82 (1.38–10.57) | 3.39 (1.39–8.30) |
> 15% | 81.4 | 30.1 | 65.5 | 10.16 (4.11–25.14) | 2.31 (0.98–5.46) | 4.39 (1.85–10.44) |
> 20% | 75.6 | 12.5 | 46.8 | 21.72 (6.58–71.65) | 3.53 (1.32–9.47) | 6.15 (2.06–18.35) |
> 200 mL | 89.5 | 40.7 | 72.8 | 12.37 (4.82–31.78) | 3.17 (1.27–7.94) | 3.90 (1.70–8.95) |
> 300 mL | 79.1 | 23.6 | 67.4 | 12.24 (4.62–32.47) | 1.83 (0.75–4.45) | 6.69 (2.51–17.80) |
> 400 mL | 67.9 | 13.3 | 34.0 | 13.84 (5.24–36.54) | 4.12 (1.77–9.60) | 3.36 (1.33–8.51) |